GTM Execution
Prove
Prove answers the question every board and PE firm eventually asks: did the work move the number? It re-scores against the same rubric captured at diagnosis, with the same evidence standard, and returns a written proof artifact suitable for a board packet or a deal process.
Re-score
Toggle the moves the operator installed
ICP clarity and segment focus
Revenue quality and mix
Retention and installed-base health
Go-to-market engine
Pricing and monetization
The board sees this expand
Modeled annual EBITDA
$1,680,000$2,463,300
NRR
96.0%100.0%
CAC payback
31.0 mo27.0 mo
Implied multiple, low end
3.5x3.5x
Rule of 40: 10-24
Implied multiple 3.5x to 5.0x
illustrative, directional, not an appraisal
The CEO read: walk into the board meeting with a before and after the board can read in five minutes.
Before/after scoreboard
Tavolo, illustrative| Dimension | Baseline | Modeled | Change |
|---|---|---|---|
| ICP clarity and segment focus | 2 | 3 | +1 |
| Competitive differentiation | 3 | 3 | even |
| Product completeness | 3 | 3 | even |
| Revenue quality and mix | 2 | 3 | +1 |
| Retention and installed-base health | 2 | 3 | +1 |
| Go-to-market engine | 2 | 3 | +1 |
| Integration and ecosystem posture | 3 | 3 | even |
| Team and operating capacity | 3 | 3 | even |
| Pricing and monetization | 2 | 3 | +1 |
What the board gets when every move is in
Tavolo, illustrativeWith every move applied, the model predicts a result. The calibration registry logs that prediction against what the company actually reported once the operating period closed.
| Metric | Modeled (predicted) | Proven (realized) |
|---|---|---|
| Growth | 15.0% | 16% |
| NRR | 103.0% | 104.0% |
| EBITDA margin | 10.0% | 11% |
| CAC payback | 23.6 mo | 22.0 mo |
Modeled EBITDA at full deployment: $2,954,000. Proven EBITDA: $3,883,000. The model sits slightly conservative of what actually happened, by design.
No competitor re-scores its own advice against what actually happened.
Tavolo Systems, Dana Reyes, and Meridian Growth Partners are fictional, illustrative data used to demonstrate the product. No real company, investor, or person is represented.
What this is
Prove answers the question that every board and every PE firm eventually asks: did the work move the number? It compares the metric baseline captured at diagnostic time against a follow-on read across the same 9 GTM dimensions. Changes are documented with the same evidence standard as the original diagnostic, not inferred from narrative.
This is available self-serve or assisted. It is most valuable when run against a documented baseline from a prior diagnostic and is typically scoped to the specific dimensions where the Operate or Quantify work was focused. The output is a written proof artifact suitable for a board packet or a deal process.
Where it sits in the sequence
Prove is the final dashboard in the GTM Execution sequence. It closes the loop started by the GTM Diagnostic. Prove needs a prior baseline to measure against; running the diagnostic first is the prerequisite.
Close the loop on the work.
Requires a prior GTM Diagnostic baseline. GTM Execution, self-serve or assisted, suitable for board-level reporting.